Trial Profile
Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 13 Feb 2017 Status changed from recruiting to completed.
- 09 Feb 2013 New trial record